Candesartan could ameliorate the COVID-19 cytokine storm.
Biomed Pharmacother
; 131: 110653, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-722385
ABSTRACT
BACKGROUND:
Angiotensin receptor blockers (ARBs) reducing inflammation and protecting lung and brain function, could be of therapeutic efficacy in COVID-19 patients.METHODS:
Using GSEA, we compared our previous transcriptome analysis of neurons injured by glutamate and treated with the ARB Candesartan (GSE67036) with transcriptional signatures from SARS-CoV-2 infected primary human bronchial epithelial cells (NHBE) and lung postmortem (GSE147507), PBMC and BALF samples (CRA002390) from COVID-19 patients.RESULTS:
Hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were similarly upregulated by glutamate and normalized by Candesartan. Gene Ontology analysis revealed expression profiles with greatest significance and enrichment, including proinflammatory cytokine and chemokine activity, the NF-kappa B complex, alterations in innate and adaptive immunity, with many genes participating in the COVID-19 cytokine storm.CONCLUSIONS:
There are similar injury mechanisms in SARS-CoV-2 infection and neuronal injury, equally reduced by ARB treatment. This supports the hypothesis of a therapeutic role for ARBs, ameliorating the COVID-19 cytokine storm.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Tetrazoles
/
Benzimidazoles
/
Coronavirus Infections
/
Angiotensin II Type 1 Receptor Blockers
/
Cytokine Release Syndrome
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Biomed Pharmacother
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS